EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center

Muruvvet Seda Aydin, Gulten Korkmaz, Merve Pamukcuoglu, Hatice Rahmet Guner, Funda Ceran, Simten Dagdas, Gulsum Ozet

Mediterranean Journal of Hematology and Infectious Diseases · 2026-04-30 · 18 (1) · e2026044

DOI: 10.4084/mjhid.2026.044 ↗
AbstractBibliografische Angaben

Abstract

Background: Ruxolitinib has been associated with an increased risk of viral infections and tuberculosis reactivation in patients with Philadelphia chromosome-negative myeloproliferative neoplasm. However, data regarding screening practices and prophylactic approaches in routine clinical care remain limited. Objective: To describe latent tuberculosis screening, antiviral prophylaxis practices, and infectious outcomes in ruxolitinib-treated patients with myeloproliferative neoplasm at a single center. Methods: Thirty patients with Philadelphia chromosome-negative myeloproliferative neoplasm treated with ruxolitinib were included in this retrospective single-center study. Results: The median duration of ruxolitinib therapy was 20.1 months. Latent tuberculosis screening was performed in nearly all patients, and isoniazid prophylaxis was administered to five individuals according to screening results. No tuberculosis reactivation occurred during follow-up. Antiviral prophylaxis was administered to 56.6% of patients. One patient developed herpes zoster during treatment, and two experienced recurrent oral herpes. Exploratory analyses did not identify statistically significant clinical factors associated with recurrent oral herpes or antiviral prophylaxis initiation. Conclusion: This study provides a descriptive real-world account of infectious outcomes and institutional screening and management practices in ruxolitinib-treated patients with Philadelphia chromosome-negative myeloproliferative neoplasm. Larger prospective studies are required to further clarify optimal screening and prophylactic strategies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →